Wells Fargo & Company Onconova Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Onconova Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 164 shares of ONTX stock, worth $96. This represents 0.0% of its overall portfolio holdings.
Number of Shares
164
Previous 161
1.86%
Holding current value
$96
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ONTX
# of Institutions
28Shares Held
1.72MCall Options Held
2.6KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA709KShares$418,0840.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny268KShares$158,2340.0% of portfolio
-
Black Rock Inc. New York, NY249KShares$146,8380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA193KShares$113,7860.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny73.1KShares$43,1080.0% of portfolio
About Onconova Therapeutics, Inc.
- Ticker ONTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,895,600
- Market Cap $12.3M
- Description
- Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...